Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

HCV life cycle-source of a new DAA (CROSBI ID 621341)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Wagner, Jasenka HCV life cycle-source of a new DAA // Program and abstracts, 1st International Monothematic Conference on Viral Hepatitis C (IMC-HCV-2014), September 11-13, Opatija, Croatia / M. Smolić, A. Včev, George Y. Wu (ur.). Osijek: Medicinski fakultet Sveučilišta Josipa Jurja Strossmayera u Osijeku, 2014. str. 42-43

Podaci o odgovornosti

Wagner, Jasenka

engleski

HCV life cycle-source of a new DAA

Hepatitis C Virus (HCV) is a positive-sense, single-stranded enveloped RNA virus approximately 9600 nucleotides in length. It belongs in the Flaviviridae family. Due to the highly error prone RNA polymerase, HCV displays remarkable genetic diversity and propensity for selection of immune evasion or drug resistance mutations. Recent HCV therapeutic development has been greatly enhanced by basic understanding of HCV virology and life cycle, through studies using HCV cell culture systems and replication assays. Since progress in understanding HCV biology has been trigger for creating a remarkably rich pipeline of direct acting antiviral compounds (DAA) in various stages of preclinical and clinical developments (phases 2 or 3 of clinical trials), this lecture will give brief overview of different viral and host cellular factors interacting in HCV life cycle steps such as viral attachment, entry, and fusion ; HCV RNA translation ; posttranslational modification ; HCV replication ; virus assembly and release. Investigated DAAs act as either NS3-NS4A protease inhibitors which interact with translation and polyprotein processing or as NS5A inhibitors or NS5B polymerase inhibitors which interact with HCV RNA replication or assembly and virion morphogenesis. At the moment, there is a large number of IFN-free clinical studies combining one, two or three antiviral agents, with or without ribavirin. However, severe side effects, resistance and drug-drug interactions are still issues, so the search for the holy grail of HCV treatment, an all-oral highly effective IFN free regimen, continues.

HCV; DAA

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

42-43.

2014.

nije evidentirano

objavljeno

978-953-7736-20-0

Podaci o matičnoj publikaciji

Program and abstracts, 1st International Monothematic Conference on Viral Hepatitis C (IMC-HCV-2014), September 11-13, Opatija, Croatia

M. Smolić, A. Včev, George Y. Wu

Osijek: Medicinski fakultet Sveučilišta Josipa Jurja Strossmayera u Osijeku

Podaci o skupu

1st International Monothematic Conference on Viral Hepatitis C (IMC-HCV-2014), September 11-13, Opatija, Croatia

pozvano predavanje

11.09.2014-13.09.2014

Opatija, Hrvatska

Povezanost rada

Temeljne medicinske znanosti, Kliničke medicinske znanosti